ProfileGDS5678 / 1430795_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 38% 38% 39% 38% 39% 45% 41% 45% 39% 40% 39% 38% 39% 39% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.9121338
GSM967853U87-EV human glioblastoma xenograft - Control 22.863938
GSM967854U87-EV human glioblastoma xenograft - Control 32.8942739
GSM967855U87-EV human glioblastoma xenograft - Control 42.8020338
GSM967856U87-EV human glioblastoma xenograft - Control 52.8512939
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.1554545
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.003641
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.0327345
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.8784739
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.8921840
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.8800139
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.8261738
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.8945939
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.8874239